Quizartinib is a potent and selective inhibitor of FLT3 (Kd = 1.6nM, IC50 = 0.56 nM MV4-11 cells). It is in clinical trials for treatment of Acute Myelogenous Leukemia (AML). Quizartinib priming resulted in prevention of myelosuppression in mice treated with 5-FU and Gemcitabine. Quizartinib...
Know who made it. See the evidence. Buy through one marketplace.
Quizartinib is a potent and selective inhibitor of FLT3 (Kd = 1.6nM, IC50 = 0.56 nM MV4-11 cells). It is in clinical trials for treatment of Acute Myelogenous Leukemia (AML). Quizartinib priming resulted in prevention of myelosuppression in mice treated with 5-FU and Gemcitabine. Quizartinib showed significant reversal of ABCG2-mediated multidrug resistance (@ 3 µM) via antagonism of drug efflux function
This product is manufactured by TriBio Science and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
FLT3 identifies fms related receptor tyrosine kinase 3 in Homo sapiens (Human). This target record connects NCBI Gene 2322, UniProtKB P36888 and related ABMIUM catalogue products.
